WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
So, here are four companies that have potentially blockbuster drugs, have already witnessed some traction in shares and are likely to offer potential high ROI to investors.
An approval by the FDA (Food and Drug Administration) throws open the gates to a drug’s or medical device’s long journey in the market. This is especially the case for companies that receive approval for treatments for more widespread diseases like depression, Alzheimer’s, obesity, diabetes, arthritis and the most dreaded of all – cancer. These blockbuster drugs, so often labelled as “breakthrough therapies,” can translate into a handsome fortune for pharma companies (and their Investors).
STRATEGY AFFECTS ROI
Quite understandably, investors flock to grab stocks of companies that have received FDA approval. Unfortunately, what most investors don’t realize is that they end up buying into the company after share prices have already surged. So, they are buying expensive, which limits their ROI. Moreover, investors need to be aware that even after an FDA approval has come through, the drug or medical device could take years to become a success.
Investors who like to play it very safe, often lose a significant amount of money (in terms of lost opportunity) without even realizing it. They look out for news of approval and then chase shares that are already on the upswing.
Smart investors follow a slightly different approach to maximize their gains. They sniff out smaller players in the healthcare industry, ensure that they have potential blockbuster candidates, and invest in shares when the price is extremely low. An investment of a few thousand dollars in the right company at the right time can yield hundreds of thousands, if not millions, on FDA clearance.
NUCLEAR POWERED PROFITS
Advanced Medical Isotope Corp. (ADMD) is a late-stage radiation oncology focused medical device company engaged in the development of Yttrium-90 (Y-90) based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.
The Y-90 brachytherapy product is able to target cells within a narrow range, minimizing damage to normal cells. Moreover, the safety profile is noteworthy. While traditional brachytherapy products emit radiation that may travel within and outside the body and have long half lives, the company’s products use the Y-90 isotope, which travels only a short distance and has a half life of merely 2.7 days. The company’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure.
In the last month of 2014 the company filed a de novo submission with the FDA for marketing clearance for its patented Y-90 RadioGel device. Investors were excited about the prospects, and the shares jumped 2,100% from $0.0003 to $0.0065 over the course of several months. If a trader made the savvy decision to to make an investment in (ADMD) at this low and rode it to the top we’re talking about gains in the neighborhood of turning $10,000 into almost a quarter million. With the Company expecting to submit to the FDA again sometime this year (with the requested data from the last submission), things are starting to look the way they did between the middle of 2014 and the middle of 2015 for this ticker.
MORE OF THE SAME IS ON ITS WAY
There is a great deal of optimism around ADMD. This is because of two reasons. Firstly, the company addresses a market that is large, and growing at a phenomenal pace. Every year, approximately 14 million people are diagnosed with cancer worldwide. And, this staggering figure is expected to surge by about 70% over the next two decades.
Secondly, the company’s products are based on radiation technology, which is the latest focus area for treatment. Radiation therapy has come to the forefront of all cancer therapies, and is already being administered to about 50% of all cancer patients. The market for radiotherapy is estimated to grow from $5.6 billion in 2015 to $8 billion by 2019.
While the company prepares to file for FDA submission, its share price is currently less than a penny. If FDA clearance is given, there is little doubt that the prospects for the company’s patented Y-90 products are very bright. It won’t be surprising to see the company’s shares surge again by more than 2,000%.
A FEW OTHER BLOCKBUSTER POTENTIALS
Agenus Inc. (AGEN) is an immuno-oncology company focused on the discovery and development of new treatments that engage the body’s immune system to benefit cancer patients. The company focuses on discovering and developing checkpoint modulators and novel vaccines for both oncology and infectious disease. In 2014, the company announced that its Agenus’ HerpV Therapeutic Vaccine for genital herpes met primary endpoint in the Phase 2 trials. The company’s shares jumped from $3 to $9.5. That’s a 217% increase! The company recently released 4Q15 revenues of $7.64 million. Analysts expect shares to reach $15. So, someone having purchased shares at $3 would enjoy an ROI of 400%.
Argos Therapeutics Inc. (ARGS) is an immuno-oncology company focused on the development and commercialization of immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos’ lead candidate, AGS-003, has entered pivotal ADAPT Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company’s shares have jumped +100% year-to-date, from $2.30 to $4.90. Analysts expect shares to reach $16, which means that investors who purchased shares at $2.30 would reap returns of almost 600%.
Cannabis Science Inc. (CBIS) is engaged in medical marijuana R&D. The company focuses on critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science works with experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. The company’s shares soared 33% on news of GW Pharmaceuticals announcing positive Phase 3 trial data for Epidiolex for the treatment of Dravet syndrome. Investors responded favorably because the latest news supports cannabinoids being able to produce compelling clinical data.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.
GET BREAKING NEWS FROM US:
To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader’s parent company is compensated $50,000 per month by Advanced Medical Isotope Corporation. The Wealthy Biotech Trader’s parent company has been compensated 100,000 restricted preferred shares of Advanced Medical Isotope Corporation by the Company and readers should understand that they will convert these preferred shares into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
SOURCE: The Wealthy Venture Capitalist